Search
Search Results
-
A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trial
BackgroundAdvanced stage marginal zone lymphoma (MZL) is an incurable indolent B-cell lymphoma, for which a wide variety of treatments ranging from...
-
Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer
BackgroundAberrant PI3K signalling is implicated in trastuzumab resistance in HER2-positive gastric cancer (GC). The role of PI3K or MEK inhibitors...
-
A novel treatment strategy for lapatinib resistance in a subset of HER2-amplified gastric cancer
BackgroundGastric cancer (GC) is one of the leading causes of cancer-related deaths worldwide. Human epidermal growth factor receptor 2 (HER2)...
-
Combination strategies to overcome drug resistance in FLT+ acute myeloid leukaemia
BackgroundAcute myeloid leukaemia (AML) remains difficult to treat despite the development of novel formulations and targeted therapies. Activating...
-
Development and safety of PI3K inhibitors in cancer
The phosphatidylinositol 3-kinase (PI3K) signalling pathway regulates cell survival, proliferation, migration, metabolism and other vital cellular...
-
A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation
BackgroundPhosphoinositide 3-kinases (PI3Ks) are critical regulators of diverse cellular functions and have emerged as promising targets in cancer...
-
Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy
The PI3K/AKT/mTOR and RAF/MEK/ERK pathways are commonly activated by mutations and chromosomal translocation in vital targets. The PI3K/AKT/mTOR...
-
CDK9 inhibition induces epigenetic reprogramming revealing strategies to circumvent resistance in lymphoma
Diffuse large B-cell lymphoma (DLBCL) exhibits significant genetic heterogeneity which contributes to drug resistance, necessitating development of...
-
PI3K Targeting in Non-solid Cancer
Despite the therapeutic progress, relapse remains a major problem in the treatment of acute lymphoblastic leukemia (ALL). Most leukemia cells that...
-
Spatial genomic, biochemical and cellular mechanisms underlying meningioma heterogeneity and evolution
Intratumor heterogeneity underlies cancer evolution and treatment resistance, but targetable mechanisms driving intratumor heterogeneity are poorly...
-
The emerging role of PI3K inhibitors for solid tumour treatment and beyond
Phosphoinositide 3-kinases (PI3Ks) play a central role in tumourigenesis with recurrent activating mutations of its p110α subunit ( PIK3CA ) identified...
-
Interleukin-6 mediates resistance to PI3K-pathway–targeted therapy in lymphoma
BackgroundThe phosphoinositol 3-kinase (PI3K) pathway is associated with poor prognosis of hematologic malignancies, providing a strong rationale for...
-
Therapeutics Targeting Cancer Stem Cell Signalling Pathways
Cancer stem cells (CSCs) are a small population of G0-arrested tumor cells. They contribute to the metastasis, recurrence, and heterogeneity of...
-
The genomic architecture of EBV and infected gastric tissue from precursor lesions to carcinoma
BackgroundEpstein-Barr virus (EBV)-associated gastric carcinomas (EBVaGCs) present unique molecular signatures, but the tumorigenesis of EBVaGCs and...
-
Investigation of Potential High Frequency Mutation Genes and Associated Molecular Mechanism in the Progression of Thyroid Cancer
The aim of this study was to identify potential high-frequency mutation (HFM) genes and associated molecular mechanisms during the progression of...
-
Insights into the tumor microenvironment of B cell lymphoma
The standard therapies in lymphoma have predominantly focused on targeting tumor cells with less of a focus on the tumor microenvironment (TME),...
-
Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer
Background:Copanlisib is a pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor with predominant PI3K- α / δ activity that has demonstrated...
-
Immunotherapies for Cancer: Bi-specific T Cell Engagers (BiTEs)
Bi-specific T cell engagers (BiTEs) are immunologically active molecules with dual specificity, concurrently binding to a tumor-associated antigen...
-
The NCI-MATCH trial: lessons for precision oncology
The NCI-MATCH (Molecular Analysis for Therapy Choice) trial ( NCT02465060 ) was launched in 2015 as a genomically driven, signal-seeking precision...
-
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
The PI3K/AKT/mTOR (PAM) signaling pathway is a highly conserved signal transduction network in eukaryotic cells that promotes cell survival, cell...
